Agenus Inc.

No quarterly financial results were reported on this call. The key clinical data cited were a Phase I study of 123 patients with MSS colorectal cancer showing a 42% 2-year survival rate and a median overall survival of 21 months, versus 10 to 14 months referenced as the best case in current standard-of-care regimens. Management also said BOT/BAL has been studied in more than 1,200 patients across 9 tumor types, and that the first-line BBOpCo trial is almost completely recruited after about a year. For the planned Phase III program, management said the trial will enroll 834 patients, randomize 1:1 versus best supportive care, and is expected to recruit over approximately 20 to 24 months. On the corporate side, Garo Armen said the Zydus transaction has cleared HSR and is expected to clear a Treasury-related hurdle in the next 2 to 3 weeks before closing.

Garo Armen’s tone was urgent and combative, framing colorectal cancer as a crisis and saying the system is failing patients by prioritizing bureaucracy over access. He repeatedly argued that BOT/BAL and related immune approaches can produce quality-of-life-preserving responses that chemotherapy cannot, and he pushed for faster regulatory action, including openness to accelerated approval. He also described Agenus as nearing an inflection point after 31 years, citing progress on the Zydus manufacturing transaction and saying the company sees “the light at the end of the tunnel.”

No CFO spoke and no formal financial statements were given. The only concrete transaction details discussed were that the Zydus deal has already cleared Hart-Scott-Rodino and is awaiting a Treasury-related hurdle expected to clear in 2 to 3 weeks before closing. On trial financing, Christopher O'Callaghan said the Canadian Cancer Trials Group is supported by the Canadian Cancer Society and other sources and that its funding model works out to about 10:1 leverage. Garo also referenced that shifting manufacturing burden to Zydus could help Agenus.

Analyst-style questions focused on what CCTG adds to the Phase III BOT/BAL study, what the money commitment looks like, whether there are gating steps to starting this year, and how the study will be designed. O'Callaghan said CCTG brings long experience running trials, plus partnerships with Australasian and French groups, and that the study will use 1:1 randomization in MSS patients versus best supportive care. He said the trial targets patients who have exhausted standard options and expects enrollment over roughly 20 to 24 months. Earlier discussion also addressed why the FDA requires large randomized trials and how the company wants regulators to adapt to faster-moving immunotherapy science.